Výsledky vyhledávání

Akademický článek

Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis

Autor: Lyn Guenther, Irina Turchin, Ron Vender, Lorne E. Albrecht, Catherine Maari, Howard Yanofsky, Vimal H. Prajapati

Publikováno v: Dermatology and Therapy, Vol 14, Iss 7, Pp 1917-1928 (2024)

Abstract Introduction An expert panel of Canadian dermatologists was assembled to develop consensus statements regarding the current landscape of topical therapies for plaque psoriasis and the place in therapy of the recently approved fixed-dose comb

Externí odkaz: https://doaj.org/article/9a376251ab6747ba8d8b8b1dd9ba6f63

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potentialCapsule Summary

Autor: Vivian Laquer, MD, Andrea Nguyen, PA-C, MS, Nicholas Squittieri, MD, Tien Nguyen, MD

Publikováno v: JAAD International, Vol 6, Iss , Pp 13-19 (2022)

Background: The effects of halobetasol propionate (HBP) lotion 0.05% on the hypothalamic-pituitary-adrenal (HPA) axis have not been previously evaluated in adolescents. Objective: To examine the effect of HBP on HPA axis suppression in patients aged

Externí odkaz: https://doaj.org/article/9b2fd133847845d3a895f520e3ec634f

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults

Autor: Reddy V, Myers B, Yang EJ, Bhutani T

Publikováno v: Clinical, Cosmetic and Investigational Dermatology, Vol Volume 13, Pp 391-398 (2020)

Vidhatha Reddy,1 Bridget Myers,1 Eric J Yang,2 Tina Bhutani1 1University of California, San Francisco, Department of Dermatology, San Francisco, CA, USA; 2Virginia Mason Medical Center, Seattle, WA, USACorrespondence: Vidhatha ReddyUniversity of Cali

Externí odkaz: https://doaj.org/article/76950fec903043058e5584888aa0df7a

Zobrazit plný text záznamu

Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits

Autor: Linda Stein Gold, Abby Jacobson, James Q Del Rosso, Nelly K Gilyadov, Mark Lebwohl, Emil Tanghetti

Publikováno v: Dermatology and Therapy

Psoriasis is a lifelong disease associated with cycles of remission and relapse. Topical treatments are the front line of psoriasis therapy for most patients and have antiproliferative, anti-inflammatory, and immunosuppressive mechanisms of action. N

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d3c82b357646b0ca11c88b68ba72e18
https://doi.org/10.1007/s13555-021-00560-6

Zobrazit plný text záznamu

Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis

Autor: Tina Bhutani, Nicholas Brownstone, John Koo

Publikováno v: Current Dermatology Reports. 10:21-25

This article reviews in detail the merits and unique nature of this combination lotion and also discusses a new type of strategy for treating psoriasis topically. The combination lotion proved much more efficacious than the vehicle. Moreover, when th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5f207b0c2d2de6ffcd8ca482c2d8d6d
https://doi.org/10.1007/s13671-020-00327-w

Zobrazit plný text záznamu

Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis

Autor: James Q Del Rosso, Abby Jacobson, Mark Lebwohl, Lawrence Green, Linda Stein Gold

Publikováno v: Journal of Dermatological Treatment. 33:2068-2074

Background The topical corticosteroid halobetasol propionate (HP) and retinoid tazarotene (TAZ) are effective in psoriasis treatment. Fixed-combination HP 0.01%/TAZ 0.045% lotion has demonstrated efficacy and safety in moderate-to-severe plaque psori

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c734469caa58719453bbc00268342ee0
https://doi.org/10.1080/09546634.2021.1914310

Zobrazit plný text záznamu

Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potential

Autor: Tien Nguyen, Andrea Nguyen, Vivian Laquer, Nicholas Squittieri

Publikováno v: JAAD International
JAAD International, Vol 6, Iss, Pp 13-19 (2022)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21b54bac107c6d89ed7973f987bbb9a7
https://pubmed.ncbi.nlm.nih.gov/34870246

Zobrazit plný text záznamu

Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants

Autor: Seemal R. Desai, Brad Glick, Susan Harris, James Q Del Rosso, Abby Jacobson

Publikováno v: Journal of Drugs in Dermatology. 20:252-258

Background Psoriasis is a chronic, inflammatory disease that may differ in prevalence and clinical presentation among patients from various racial and ethnic groups. Two phase 3 studies demonstrated efficacy and safety of halobetasol propionate (HP)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b9c292d13e835eb9be7858d3ec16678
https://doi.org/10.36849/jdd.5698

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání